At a glance
ClinicalIndex Comparison Record- ✓Biopsy-proven intrahepatic hepatocellular carcinoma or neuroendocrine tumor
- ✓Unresectable disease
- ✓Bidimensionally measurable disease on imaging (CT, MRI, or ultrasound) within 6 weeks of registration
- ✓Patent portal vasculature confirmed by Doppler ultrasound, MRI, or angiography
- ✕Extrahepatic disease likely to be life-threatening within 3 months, such as brain or symptomatic lung metastases
- ✕Prior intra-arterial or intra-hepatic chemotherapy or systemic chemotherapy within 4 weeks
- ✕Concurrent malignancy
- ✕Pregnant or breast-feeding women
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial
In Brief
A Phase 2 clinical trial evaluating cisplatin, doxorubicin, and 2 other interventions for Liver Cancer and Metastatic Cancer. Completed, enrolled 50 participants across 37 sites.
Detailed Summary
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.
Study Details
Timeline
Interventions
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.